Thamm K, Njau F, Van Slyke P, Dumont DJ, Park JK, Haller H, David S.
World J Transplant. 2016 Sep 24;6(3):573-82.
Thamm K, Njau F, Van Slyke P, Dumont DJ, Park JK, Haller H, David S.
World J Transplant. 2016 Sep 24;6(3):573-82.
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.